References
- Abdelwahed W, Degobert G, Stainmesse S, Fessi H. (2006). Freeze drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev 58:1688–713
- Cavalli R, Caputo O, Carlotti ME, et al. (1997). Sterilization and freeze drying of drug free and drug loaded solid lipid nanoparticles. Int J Pharm 148:47–54
- De Jong WH, Hagens WI, Krystek P, et al. (2008). Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials 29:1912–9
- Doijad RC, Manvi FV, Godwani DM, et al. (2008). Formulation and targeting efficiency of cisplatin engineered solid lipid nanoparticles. Indian J Pharm Sci 70:203–7
- Gallarate M, Trotta M, Battaglia L, Chirio D. (2009). Preparation of solid lipid nanoparticles from W/O/W emulsions: preliminary studies on insulin encapsulation. J Microencapsul 26:394–402
- Garnett MC, Kallinteri P. (2006). Nanomedicines and nanotoxicology: some physiological principles. Occup Med 56:307–11
- Hirn S, Behnke MS, Schleh C, et al. (2011). Particle size dependent and surface charge dependent biodistribution of gold nanoparticles after intravenous administration. Eur J Pharm Biopharm 77:407–16
- Jia L, Zheng JJ, Jiang SM, Huang KH. (2010). Preparation, physicochemical characterization and cytotoxicity in vitro of gemcitabine loaded PEG-PDLLA nanovesicles. World J Gastroenterol 16:1008–13
- Jelvehgari M, Barar J, Valizadeh H, Heidari N. (2010). Preparation and evaluation of poly (ε-caprolactone) nanoparticles-in-microparticles by W/O/W emulsion method. Iran J Basic Med Sci 13:85–96
- Konan YN, Gurny R, Allemann E. (2002). Preparation and characterization of sterile and freeze-dried sub-200nm nanoparticles. Int J Pharm 233:239–52
- Li JM, Chen W, Wang H, et al. (2009). Preparation of albumin nanospheres loaded with gemcitabine and their cytotoxicity against BXPC-3 cells in vitro. Acta Pharmacol Sin 30:1337–43
- Luo YF, Chen DW, Ren LX, et al. (2006). Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J Control Release 114:53–9
- Muhlen AZ, Schwarz C, Mehnert W. (1998). Solid lipid nanoparticles (SLN) for controlled drug delivery – drug release and release mechanism. Eur J Biopharm 45:149–55
- Reddy LH, Dubernet C, Mouelhi SL, et al. (2007). A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types. J Control Release 124:20–7
- Sacchi A, Gasparri A, Gallo Stampino C, et al. (2006). Synergistic antitumor activity of cisplatin, paclitaxel and gemcitabine with tumor vasculature-targeted tumor necrosis factor-α. Clin Cancer Res 12:175–82
- Sarlo K, Blackburn KL, Clark ED, et al. (2009). Tissue distribution of 20 nm, 100 nm and 1000nm fluorescent polystyrene latex nanospheres following acute systemic or acute and repeat airway exposure in the rat. Toxicology 263:117–26
- Sarmento B, Martins S, Ferreira D, Souto EB. (2007). Oral insulin delivery by means of solid lipid nanoparticles. Int J Nanomed 2:743–9
- The European Agency for the Evaluation of Medicinal Products. (2003). Stability testing guidelines: stability testing of new drug substances and products. London: ICH-Technical Coordination, EMEA. Available from: http://www.emea.eu.int [last accessed 20 Feb 2003]
- Tsai YM, Chien CF, Lina LC, Tsai TH. (2011). Curcumin and its nano formulation: the kinetics of tissue distribution and blood brain barrier penetration. Int J Pharm 416:331–8
- Utreja S, Jain NK. (2002). Solid lipid nanoparticles: controlled and novel drug delivery. 1st ed. : CBS Published and Distributors, 408–25
- Werle M, Bemkop Schnurch A. (2006). Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 30:351–67
- Wissing SA, Kayser O, Muller RH. (2004). Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56:1257–72